Amgen to present results from Phase 3 ENDEAVOR trial

Amgen's positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial.
“Results from the ENDEAVOR primary analysis proved KYPROLIS is the superior proteasome inhibitor, having doubled progression-free survival compared to Velcade," Dr. Meletios Dimopoulos, professor of Clinical Therapeutics at the National and Kapodistrian University of Athens, said. "Results presented today showed that progression-free survival advantage translated into significantly improved survival for patients, a clinical endpoint that creates confidence for physicians and patients, especially in a relapsing disease like multiple myeloma."
In the study, ENDEAVOR met its key secondary endpoint, showing that patients treated with KYPROLIS and dexamethasone lived 7.6 months longer than patients who were treated with velcade and dexamethasone. The company will present all the results at the 16th International Myeloma Workshop (IMW) in New Delhi, during the late-breaking abstract session.
"We are proud to share these results with leading multiple myeloma experts at IMW as we continue to explore the complex biology of treating this presently incurable disease," Dr. Sean Harper, Amgen's executive vice president of Research and Development, said. "KYPROLIS continues to demonstrate advancement in proteasome inhibition, and we look forward to submitting these findings to regulatory agencies worldwide to support a potential label update."